摘要
目的观察进展期胃癌患者术后早期腹腔低渗热灌注化疗联合静脉化疗的临床治疗效果。方法对我院5年间133例进展期胃癌患者随机分为腹腔热灌注化疗联合全身化疗组(治疗组,n=63)及单纯全身化疗组(对照组,n=70),治疗组行根治性胃切除术后行腹腔低渗热灌注保留化疗4次,之后行FOL-FOX6化疗方案静脉化疗。对照组则于根治性胃切除术后单纯FOLFOX6化疗方案静脉化疗。对其临床效果与预后进行对照观察。结果①治疗组KPS评分升高率52.38%,对照组为41.42%,两组KPS升高率比较有显著差异(p<0.05),而两组间副反应发生率无明显差异(p>0.05),均无发生严重并发症。②治疗组术后1年、3年、5年生存率分别为93.62%、70.75%、43.58%;对照组术后1年、3年、5年生存率分别为90.00%、58.44%、34.56%,两组术后1年生存率比较,无明显差异(p>0.05),而两组术后3、5年生存率比较,则有明显差异(p<0.05)。结论术后早期腹腔低渗热灌注化疗联合静脉化疗能较为有效地提高胃癌术后生存率、生存质量,并且毒副作用小、并发症少,是目前胃癌综合治疗中较为合理的手术后辅助治疗方式。
Objective To evaluate the effects and toxicities of the hyperthermic peritoneal perfusion chemotherapy （HPPC） combined with venous chemotherapy for the treatment of advanced gastric cancer. Methods 133 cases of advanced gastric cancer were randomly divided into treatment group and control group. One week after radical gastrectomy, 5 -Fu （500 mg/m^2） ＋ Cisplatin （100 mg/m^2） were used for HPPC at 43 ℃ weekly for four weeks, then the FOLFOX6 chemotherapy plan was carried out monthly for six months in treatment group. Whereas the control group was received FOLFOX6 chemotherapy plan monthly for six months only. The postoperative survival rate （ 1, 3 and 5year）, side effects and complications, KPS scores of patients were compared between the two groups. Results ①KPS scale increasing rate was 52. 38% in treatment group versus 41.42% in control group respectively （p 〈 0. 05 ）, but the side effects rate was the same and there were no severe complications occurred. ②The 1, 3, and 5year survival rates in trehtment group were 93.62% ,70. 75% and 43.58% ;and in control group 90. 00% ,58.44% and 34.56% respectively. The 3 and 5year survival rates were significantly different between the two the groups （p 〈 0. 05）. Conclusion HPPC is safe, feasible, when combined with venous chemotherapy, it can improve the progno- sis and raise survival rate of the advanced gastric cancer patients significantly.
出处
《现代医院》
2008年第12期12-14,共3页
Modern Hospitals
关键词
胃肿瘤
腹腔灌注疗法
高温低渗液化疗
生存率
Stomach neoplasm, Peritoneal infusion, Hyperthermic peritoneal perfusion chemotherapy, Curative Effect
